In summary, GEN may serve as a targeted estrogen replacement strategy by activating the GPER/PI3K/AKT pathway to enhance GLUT4 expression and membrane translocation, thereby improving postmenopausal glucose metabolic disorders while avoiding typical estrogen-related adverse effects. The gene discussed is AKT1; the disease is glucose metabolism disease.